COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01330498
Recruitment Status : Completed
First Posted : April 7, 2011
Last Update Posted : January 6, 2012
Information provided by (Responsible Party):
John F. Foley, MD, Rocky Mountain MS Research Group, LLC

Brief Summary:
This is an open-label study of patients with relapsing forms of Multiple Sclerosis designed to assess the longitudinal pharmacokinetic, pharmacodynamic, immunological, and biochemical sample collection with MRI and relapse analysis of a Tysabri patient cohort. The study hopes to identify secondary and tertiary risk stratification markers that would aid in the clinical management of patients who are JC antibody positive.

Condition or disease
Multiple Sclerosis

Detailed Description:
Progressive multifocal leukoencephalopathy (PML) has been related to the utilization of Tysabri as a therapeutic agent in the treatment of multiple sclerosis. The etiologic agent is the human polyomavirus JC. PML can result from lytic infection of glial cells via a mutant JC virus in multiple sclerosis patients being actively treated with Tysabri. The mutated JC virus is a neurotrophic virus that infects only humans. "The regulatory region sequence of the JC virus is hypervariable and contains determinants for neurotropism and neurovirulence." (Jensen and Major, 2001). In patients initially infected for the most part in childhood the virus tends to remain quiescent in kidneys, bone marrow and lymphoid tissue. The true incidence of JC virus seroprevalance is currently being assessed via two Biogen Idec clinical trials (STRATIFY 1 101JC401 and STRATIFY 2 101JC402). Application has been made to the FDA regarding a label change for Tysabri which will incorporate the use of the JC antibody assay. Upon FDA approval of the label change, the JC assay will serve as a primary risk stratification tool in the clinical use of Tysabri. Secondary and tertiary risk stratification markers would greatly aid in the clinical management of patients who are JC antibody positive.

Layout table for study information
Study Type : Observational
Actual Enrollment : 229 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical Sample Collection With MRI and Relapse Analysis of a Tysabri Patient Cohort
Study Start Date : April 2011
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Natalizumab

Tysabri (natalizumab) infusing
Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).

Primary Outcome Measures :
  1. Duration Effect of natalizumab [ Time Frame: 18 months ]
    Primary: To further understand the duration effect of natalizumab at the biochemical, cellular, and pharmacokinetic levels in natalizumab patients; identify biomarkers which could aid in patient risk modification for (PML). Assess the stability of natalizumab concentration via pharmacokinetic measurement in ug/ml.

Secondary Outcome Measures :
  1. Stability of cell trafficking inhibition [ Time Frame: 18 months ]
    Secondary endpoint: Assess the stability of cell trafficking inhibition produced through steady state Natalizumab administration through an infusion cycle. Cell trafficking is measured via sVCAM, measurement units ng/mL.

Biospecimen Retention:   Samples Without DNA
Serum for PK/PD, SVCAM back-up samples will be kept.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with relapsing forms of MS. Conducted at one site in the US. Subjects currently enrolled in TOUCH Prescribing Program, and participated in Foley 001-001-TY eligible.

Subset of approx. 40 patients to participate in Part B. 11 high risk bivalent patients 11 low risk monovalent patients 9 patients who participated in 2009 PK/PD study (Biogen Idec, 101MS406) 9 patients with infusion cycle of 38 days plus or minus 2 days

Part C "Intracellular energetic in Tysabri therapy":

Patients whose iATP fell into the bottom 20th percentile will be asked to participate in a sub-study that includes Part A with the addition of collecting iATP. This number is approximately 50 participants.

Part D patients from 001-001-TY with low or normal IgG4 levels will be asked to participate in sub-study for an additional IgG4 assay collected at 3-5 days post-infusion. This number is approximately 30 participants.


Inclusion Criteria:

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  • Aged 18 to 80 years old, inclusive, at the time of informed consent.
  • Must be a patient with a relapsing form of Multiple Sclerosis enrolled in the TOUCH Prescribing Program who is not expected to discontinue Tysabri® therapy prior to completion of the requirements of this study.
  • Must have participated in IIT I (Foley, IIT 1 001-001-TY) in March, April, or May of 2010.
  • Must have a magnetic resonance imaging (MRI) brain scan, performed prior to the initiation of treatment with natalizumab, on file.
  • Must weigh between 38 and 180 kg, inclusive.
  • Up to 40 patients will be asked to also participate in Part B, the PK/PD subset,
  • Approximately fifty patients will be asked to also participate in the sub-study Part C. These patients will have been in the bottom 20th percentile for iATP in Foley IIT 1 001-001-TY.

Exclusion Criteria:

  • If subject answers 'Yes" to any question on the PML questionnaire that is not resolved prior to infusion as per standard operating procedure for natalizumab infusion.
  • If subject consumes alcohol within 24 hours of blood specimen collection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01330498

Layout table for location information
United States, Utah
Rocky Mountain Multiple Sclerosis Clinic
Salt Lake City, Utah, United States, 84103
Sponsors and Collaborators
John F. Foley, MD
Layout table for investigator information
Principal Investigator: John F Foley, MD Rocky Mountain MS Research Group, LLC
Layout table for additonal information
Responsible Party: John F. Foley, MD, Sponsor-Ivestigator, Rocky Mountain MS Research Group, LLC Identifier: NCT01330498    
Other Study ID Numbers: 001-002-TY
First Posted: April 7, 2011    Key Record Dates
Last Update Posted: January 6, 2012
Last Verified: January 2012
Keywords provided by John F. Foley, MD, Rocky Mountain MS Research Group, LLC:
Longitudinal assessment of biomarkers
duration of natalizumab
stratification of risk for PML
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases